CN110227085A - Application of the Akkermansia Muciniphila in preparation antidepressant or health care product - Google Patents
Application of the Akkermansia Muciniphila in preparation antidepressant or health care product Download PDFInfo
- Publication number
- CN110227085A CN110227085A CN201910639110.5A CN201910639110A CN110227085A CN 110227085 A CN110227085 A CN 110227085A CN 201910639110 A CN201910639110 A CN 201910639110A CN 110227085 A CN110227085 A CN 110227085A
- Authority
- CN
- China
- Prior art keywords
- bacterium
- depression
- akkermansia muciniphila
- health care
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000702462 Akkermansia muciniphila Species 0.000 title claims abstract description 57
- 230000036541 health Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 230000001430 anti-depressive effect Effects 0.000 title description 6
- 239000000935 antidepressant agent Substances 0.000 title description 5
- 229940005513 antidepressants Drugs 0.000 title description 5
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 19
- 230000000968 intestinal effect Effects 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 241000894006 Bacteria Species 0.000 claims description 26
- 210000000936 intestine Anatomy 0.000 claims description 5
- 238000009928 pasteurization Methods 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 239000003124 biologic agent Substances 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 12
- 208000020401 Depressive disease Diseases 0.000 abstract description 8
- 230000000994 depressogenic effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 238000012048 forced swim test Methods 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 3
- 238000010172 mouse model Methods 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 37
- 239000000047 product Substances 0.000 description 15
- 238000001514 detection method Methods 0.000 description 8
- 230000003001 depressive effect Effects 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- -1 1g/l) Chemical compound 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000702460 Akkermansia Species 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000754688 Cercaria Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241001148134 Veillonella Species 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of application of Akkermansia Muciniphila bacterium in the drug or health care product of preparation prevention and treatment depression.The present invention has carried out internal pharmacodynamic study to effect of the AkkermansiaMuciniphila bacterium in depression morbidity and antidepression, and the AkkermansiaMuciniphila abundance in patients with depression enteron aisle is substantially reduced as the result is shown.Results of animal shows that depressed mouse intestinal Akkermansia Muciniphila abundance significantly reduces.The present invention gives the transplanting of Akkermansia Muciniphila bacterium to depressed mouse model, experiment shows, the transplanting of Akkermansia Muciniphila bacterium can promote the move distance of mouse and reduce the dead time of tail-suspention test and forced swim test, the significant depressive state for alleviating mouse, show good antidepression curative effect, and no side effects.
Description
Technical field
The present invention relates to a kind of probiotics, and in particular to Akkermansia Muciniphila in antidepressant or
New application in health care product, belongs to pharmaceutical technology field.
Background technique
Depression is with the persistently low mental disorder for main clinical characteristics of significant mental state.Its clinic is often accompanied by
Mental state is low, depression of feeling oneself inferior or even conamen or behavior, and most of patients has the tendency that recurrent exerbation.Therefore, depression
It is a kind of disease of high disability rate.According to the World Health Organization (WHO) report, in general population every 100 people just have 15 people by
Arrived the puzzlement of depression.The annual expense for treating depression accounts for the 12.3% of medical total expenditure.And in China, it is estimated to be
20000000-5,000 ten thousand patients with depression, and illness rate increases year by year, and not yet safely and effectively antidepression is biological for existing market
Preparation.
Although the factors such as the morbidity of depression and heredity, neuroendocrine, nerve immunity, body fluid are closely related,
The exact cause of disease is not known.A large number of studies show that, intestinal flora plays important during depression in recent years
Role.Intestinal flora affects the function and behavior of brain by " intestines-brain axis ".Clinical research discovery, patients with depression excrement
Middle actinomyces, lactobacillus, streptococcus, the bacteriums such as cercaria clostridium significantly increase and bacteroid, sour coccus, the bacteriums such as Veillonella
It significantly reduces, animal experiment study shows to transplant in the excrement of depressive patient to germfree mouse, and behavior depression is presented in mouse.
Akkermansiamuciniphila is a kind of 2004 identified strains come out, is universal in human gut
Existing fungal component, about accounting 3-5%.Akkermansiamuciniphila has been found and fat, type-II diabetes, solitarily
The chronic diseases such as disease are closely related.However it yet there are no its report in prevention and treatment depression.
Summary of the invention
Goal of the invention: the present invention passes through clinical detection on the basis of Akkermansiamuciniphila exercise use
Its clinical efficacy is screened in data analysis and zoopery, develops its newly answering in the drug or health care product of preparation prevention and treatment depression
With.
Technical solution: in order to achieve the goal above, the technical scheme adopted by the invention is as follows:
Akkermansia Muciniphila bacterium answering in the drug or health care product that preparation prevents and treats depression
With.
Akkermansia Muciniphila bacterium prevents and treats drug or the guarantor that intestines problem merges depression in preparation
Application in strong product.Preferably, the intestines problem includes enteritis, intestinal canal tumour.
Akkermansia Muciniphila bacterium prevents and treats drug or the health care of Patients with Diabetes Accompanied by Depression in preparation
Application in product.
Akkermansia Muciniphila bacterium prevents and treats drug or the health care of Patients with Diabetes Accompanied by Depression in preparation
Application in product.
Akkermansia Muciniphila bacterium prevents and treats the fat drug or health care product for merging depression in preparation
In application.
Akkermansia Muciniphila bacterium prevents and treats the drug or health care product that epilepsy merges depression in preparation
In application.
It is a kind of with prevention and treatment depression biological agent, it include Akkermansia Muciniphila bacterium or
Akkermansia Muciniphila fungus extract.
Preferably, above-described application, the Akkermansia Muciniphila bacterium bag is included
Bacterium after Akkermansia Muciniphila viable bacteria or pasteurization.
The utility model has the advantages that compared to the prior art, the present invention has the following advantages:
(1) present invention is screened on clinical detection data analysis foundation by a large amount of zoopery, is furtherd investigate, is mentioned
For new application of the Akkermansia Muciniphila in antidepressant.The present invention is knocked out using flora and caprophyl transplanting
Technology, the experimental results showed that, Akkermansia Muciniphila transplanting can promote the move distance of mouse and reduce outstanding tail
The dead time of experiment and forced swim test, the significant depressive state for alleviating mouse prompt Akkermansia
Muciniphila has good antidepression curative effect, clinically can be used for preparing the drug for the treatment of depression.
(2) the experimental results showed that Akkermansia Muciniphila, curative effect is reliable, use is safe, has no toxic side effect,
It can be used for preparing the drug or health food of prevention and treatment depression.
(3) it is a discovery of the invention that Akkermansia Muciniphila viable bacteria or pass through the dead bacterium of pasteurization, for metabolism
Disease shows preferably effective and safe.The present invention has found by comparison, equally safe for depressive patient, and
Viable bacteria and dead bacterium are equally effective.
Detailed description of the invention
Fig. 1 is that chronic restricted stress causes mouse depression sample state to flora and Akkermansia Muciniphila phase
To the influence diagram of abundance.
Fig. 2 is spacious field experimental result picture.(normal group is compared, P < 0.05 *；Compared with depressed group,#P<0.05)
Fig. 3 be tail-suspention test result figure (compared with normal group, P < 0.05 *；Compared with depressed group,#P<0.05)。
Fig. 4 be forced swim test result figure (compared with normal group, P < 0.05 *；Compared with depressed group,#P<0.05)。
Specific embodiment
According to following embodiments, the present invention may be better understood.However, as it will be easily appreciated by one skilled in the art that real
It applies specific material proportion, process conditions and its result described in example and is merely to illustrate the present invention, without that should will not limit
The present invention described in detail in claims processed.
Embodiment 1
1, the preparation method of Akkermansia Muciniphila bacterium solution:
The Akkermansia Muciniphila bacterium solution for taking 1ml, is added in the brain heart oxoid meat soup of 10ml, in 37 DEG C
After cultivating 72h under anaerobic environment, by bacterium solution centrifugation (6000rpm) 20 minutes, supernatant is separated, with sterile PBS solution by bacterium solution
Allotment obtains Akkermansia Muciniphila bacterium solution (abbreviation AKK bacterium solution) to OD600=1.
2, clinical fecal sample preparation method:
Each 5 parts of healthy and depressed volunteer's excrement collected are chosen, sample mixing processing is carried out for every group of fecal sample, it will
The excrement of sample mixing processing is dissolved in sterile PBS, and by bacterium solution centrifugation (1000rpm) 10 minutes, it is spare to take out supernatant.
3, intestinal flora knocks out modeling
6-8 weeks C57BL/6 male mice is taken routinely to drink broad-spectrum antibiotic daily, it is for 4 weeks.Broad-spectrum antibiotic includes ammonia
Benzyl XiLin (Ampicillin, 1g/l), metronidazole (Metronidazole, 1g/l), neomycin (Neomycin, 1g/l) or ten thousand
Ancient mycin (Vancomycin, 500mg/l).
4, caprophyl is transplanted
After intestinal flora knocks out modeling, by C57 mouse 30,3 groups is randomly divided into, every group 10, is positive respectively
Normal group, depressed group, AKK treatment group, normal group mouse give Healthy People caprophyl 0.1ml and sterile PBS solution 0.1ml daily；Suppression
Strongly fragrant group of mouse gives depressive patient caprophyl 0.1ml and sterile PBS solution 0.1ml daily；AKK treatment group mouse gives depression daily
Patient's caprophyl 0.1ml and AKK bacterium solution 0.1ml.Behaviouristics detection, behaviouristics inspection are carried out to mouse after caprophyl transplants modeling
Survey includes: spacious field experiment, tail-suspention test and forced swim test.
5, chronic restricted stress model is constructed
It constructs chronic restricted stress depression mouse model (Chronic restraint stress, CRS).CRS is current
More generally acknowledged depression model both at home and abroad, specific modeling method are as follows: take male C57BL/6 mouse, the age was at 6-8 weeks.It adapts to
Property feed 1 week after, mouse is seated in 0.5mm diameter daily, 3h in the centrifuge tube of 50ML continues 30 days.It was recorded at the 30th day
Performance testing result.During CRS modeling, remaining each group limits mouse feeding and water supply；Experiment terminates to carry out all mouse
Behaviouristics detection, behaviouristics detection include: spacious field experiment, tail-suspention test and forced swim test.
6, mice behavior detects
(1) spacious field is tested
Mouse is put into black wooden case to the corner of the cell (45cm ╳ 45cm ╳ 45cm), after adapting to 1 minute, with video meter
All spontaneous activities in 5 minutes after calculation machine tracking system record.Using total move distance as the index of motor activity.
(2) tail-suspention test
Adhesive tape is placed on away from about 2 centimeters of tail end, and mouse is suspended at the 50cm of ground.Every mouse is placed
6min, and the mouse dead time is recorded in seconds in last 4min.Dead time is defined as not escaping the row of guiding
For.When mouse does not have any body kinematics, they be considered as it is static, passively and completely fixedly hang over together.
(3) forced swim test
Mouse is placed in 30cm ╳ 45cm water tank, and water temperature is maintained at 27 DEG C.Every mouse places 6min, and last
4min records the mouse dead time in seconds.Dead time refers to that animal is floated in water without struggling, and need to only do
Movement is just able to maintain the time that head is higher than the water surface.Then, experiment mice is placed under warming lamp and dries.
7, Akkermansia Muciniphila flora sample extraction
According to the explanation of manufacturer, applicationExtracting tool (Omega Bio-tek, Norcross, GA,
U.S.), clinical fecal sample and mouse cecal content sample are subjected to DNA extraction.Light is divided using Nano-Drop 1000
Degree meter (Thermo Scientific Inc., Wilmington, DE, USA) determines DNA concentration.Pass through F338 (5 '-
ACTCCTACGGGAGGCAGCA-3 ') and R806 (5 '-GGACTACHVGGGTWTCTAAT-3 ') primer pair bacterium 16s rRNA base
Because V3-V4 Variable Area is expanded.3 repetitions of each sample, by the polymerase chain reaction (Polymerase of same sample
Chain Reaction, PCR) product mixing after with 2% agarose gel electrophoresis detect, use AxyPrepDNA gel recycling examination
Agent box (AXYGEN company) gel extraction PCR product, Tris_HCl elution；The detection of 2% agarose electrophoresis.Amplicon is from 2% fine jade
It is extracted in lipolysaccharide glue.All PCR products pass through AxyPrep DNA gel extraction equipment (Axygen Biosciences company)
It is purified.Referring to the preliminary quantitative result of electrophoresis, by PCR product QuantiFluorTM- ST blue-fluorescence quantitative system
(Promega company) detect quantitatively, later according to the sequencing amount requirement of each sample, carries out the mixing of corresponding proportion.?
Equal molecules, 250bp both-end sequencing analysis are carried out to the PCR product of extraction on Illumina MiSeq platform.Original pyrophosphoric acid is surveyed
Sequence sequence uploads to the database SRA (Sequence Read Archive) of NCBI data center.
7, Akkermansia Muciniphila flora is analyzed
The sequence of high quality merges overlapping and generates fastq file.It will be exported by QIIME (version 1.9.1) software
Fastq file carry out multipath decoding and Quality Control filtering.Quality Control filter criteria are as follows: (1) filter 20 or less read Quality of Tail value
Base, the window of 50bp is set, if the average mass values in window be lower than 20, rear end base, mistake are clipped since window
50bp read below after filtering medium control；(2) according to the overlap relationship between PE reads, pairs of reads is spliced
(merge) at a sequence, minimum overlap length is 10bp；(3) splice the maximum mispairing that the area overlap of sequence allows
Ratio is 0.2, and screening does not meet sequence；(4) sample is distinguished according to the barcode at sequence head and the tail both ends and primer, and adjusts sequence
Column direction, the mispairing number that barcode allows are 0, and maximum primer mispairing number is 2；Chimera sequence is gone using UCHIME software
It removes, and is gathered the section of 97% similitude by UPARSE (version 7.1http: //drive5.com/uparse/) software
Symphysis is at OUTs.Pass through RDA classifier (http://rdp.cme.msu.edu/) and and silva (SSU115) 16S rRNA number
It is compared according to library and classification is compared in each OUT (door level and category are horizontal).
8, it statisticallys analyze
Data useIt indicates, is tested using one-way analysis of variance (ANOVA), p < 0.05 is that difference has system
Meter learns meaning.
9, experimental result
(1) the above flora analysis method is pressed, the Akkermansia of healthy population and depressive patient is tested and analyzed
Muciniphila relative abundance.As shown in table 1, depressive patient Akkermansia Muciniphila is equal compared with healthy population abundance
Value significantly reduces, and prompting Akkermansia Muciniphila to reduce is pathogenic one of the factor of depression in patients.
Influence of 1. depression of table to Akkermansia Muciniphila relative abundance in flora
* p < 0.05 is compared with healthy population
(2) as shown in Table 2 and Fig. 1, chronic restricted stress experiment duplication mouse depressive state, bacteria detection discovery
Akkermansia Muciniphila bacterium abundance significantly lowers, and further verifying Akkermansia Muciniphila reduction can
It can be one of pathogenic principal element of depression in patients.
2 chronic restricted stress of table causes mouse depression sample state opposite to flora and Akkermansia Muciniphila
The influence of abundance
* p < 0.05 is compared with blank group
(3) depressive patient caprophyl transplantation experiments are found, depressive state occurs in transplanting mouse, and intestinal flora and depression is prompted to close
System closely, but after taking orally above-mentioned AKK bacterium, can effectively improve the depressive state of mouse.
As shown in Fig. 2, spacious field experiment in, compared with normal group, depression group mouse mobile total distance significantly reduce (P <
0.05) after, AKK bacterium is intervened by oral administration, the mobile total distance of mouse significantly increases (P < 0.05).
As shown in figure 3, in tail-suspention test, compared with normal group, the dead time of depression group mouse significantly increase (P <
0.05) after above-mentioned AKK bacterium is intervened, but by oral administration, the dead time of mouse significantly reduces (P < 0.05).
As shown in figure 4, compared with normal group, the dead time of depression group mouse is significantly increased in forced swim test
(P < 0.05), after AKK bacterium is intervened by oral administration, the dead time of mouse significantly reduces (P < 0.05).
(4) safety detection prompts strain transplanting safety before and after mouse transplanting Akkermansia Muciniphila bacterium
Effectively.
The present invention transplants front and back mouse blood routine, liver function, renal function, spleen to Akkermansia Muciniphila bacterium
Popular name for reason, hepatic pathology are detected, and do not find toxic side effect.
The experimental results showed that, the depressive patient excrement that AKK bacterium lacks is transplanted and knocks out mouse, mouse to intestinal flora as above-mentioned
In depressed sample state.By oral administration after the treatment of AKK bacterium, the depressive state of mouse is significantly improved.The above result shows that the present invention provides
AKK bacterium have effects that well it is antidepressant.
Dead bacterium of the present invention by Akkermansia Muciniphila after pasteurization, is equally cooked the above experiment, experiment
The result shows that all having antidepressant effect.Therefore, the Akkermansia Muciniphila bacterium or pasteurization that the present invention screens
Dead bacterium afterwards acts not only as food, uses in health care product, can be used for preparing drug, existing therapeutic effect also has pre-
Anti- effect.
The present invention is studies have shown that Akkermansia Muciniphila bacterium is not only effective to patients with depression, but also to one
As crowd's depressive state it is effective.
The present invention is according to the above method studies have shown that the extract of Akkermansia Muciniphila bacterium presses down prevention and treatment
Strongly fragrant disease is equally effective.
The technical concepts and features of embodiment of above only to illustrate the invention, its object is to allow be familiar with technique
People understands the content of present invention and is implemented, and it is not intended to limit the scope of the present invention, and all spirit according to the present invention is real
The equivalent change or modification that matter is done, should be covered by the scope of protection of the present invention.
Claims (10)
- Application of the 1.Akkermansia Muciniphila bacterium in the drug or health care product that preparation prevents and treats depression.
- 2.Akkermansia Muciniphila bacterium prevents and treats drug or the health care that intestines problem merges depression in preparation Application in product.
- 3.AkkermansiaMuciniphila bacterium prevents and treats the drug or health care product of Patients with Diabetes Accompanied by Depression in preparation In application.
- 4.AkkermansiaMuciniphila bacterium prevents and treats the drug or health care product of Patients with Diabetes Accompanied by Depression in preparation In application.
- 5.AkkermansiaMuciniphila bacterium prevents and treats in the fat drug or health care product for merging depression in preparation Application.
- 6.AkkermansiaMuciniphila bacterium is in the drug or health care product that preparation prevents and treats that epilepsy merges depression Application.
- 7.AkkermansiaMuciniphila bacterium answering in the drug or health care product that preparation prevents and treats post-natal depression With.
- 8. Akkermansia Muciniphila bacterium according to claim 2 prevents and treats intestines problem in preparation and closes And depression drug or the application in health care product, which is characterized in that the intestines problem includes enteritis, intestinal canal tumour.
- 9. application according to any one of claims 1 to 8, which is characterized in that the Akkermansia Muciniphila bacterium bag includes the bacterium after Akkermansia Muciniphila viable bacteria or pasteurization.
- 10. a kind of biological agent with prevention and treatment depression, which is characterized in that it includes Akkermansia Muciniphila Bacterium or extract based on Akkermansia Muciniphila bacterium.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910639110.5A CN110227085A (en) | 2019-07-16 | 2019-07-16 | Application of the Akkermansia Muciniphila in preparation antidepressant or health care product |
| CN201911126003.9A CN110693917B (en) | 2019-07-16 | 2019-11-18 | Application of Akkermansia Muciniphila in preparation of antidepressant or health-care product |
| PCT/CN2020/079604 WO2021008149A1 (en) | 2019-07-16 | 2020-03-17 | Application of akkermansia muciniphila in preparation of antidepressant drug or health care product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910639110.5A CN110227085A (en) | 2019-07-16 | 2019-07-16 | Application of the Akkermansia Muciniphila in preparation antidepressant or health care product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110227085A true CN110227085A (en) | 2019-09-13 |
Family
ID=67855050
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910639110.5A Pending CN110227085A (en) | 2019-07-16 | 2019-07-16 | Application of the Akkermansia Muciniphila in preparation antidepressant or health care product |
| CN201911126003.9A Active CN110693917B (en) | 2019-07-16 | 2019-11-18 | Application of Akkermansia Muciniphila in preparation of antidepressant or health-care product |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911126003.9A Active CN110693917B (en) | 2019-07-16 | 2019-11-18 | Application of Akkermansia Muciniphila in preparation of antidepressant or health-care product |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN110227085A (en) |
| WO (1) | WO2021008149A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111938158A (en) * | 2020-08-18 | 2020-11-17 | 王意 | Composition for preventing reduction of abundance of Akkermansia muciniphila bacteria in intestinal tract |
| WO2021008149A1 (en) * | 2019-07-16 | 2021-01-21 | 江苏省中医院 | Application of akkermansia muciniphila in preparation of antidepressant drug or health care product |
| CN113322202A (en) * | 2021-05-31 | 2021-08-31 | 君维安(武汉)生命科技有限公司 | Ackermanella, culture method and application thereof |
| WO2023123613A1 (en) * | 2021-12-30 | 2023-07-06 | 浙江大学 | Bipolar affective disorder biomarker and use thereof |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111321089B (en) * | 2018-12-17 | 2022-03-15 | 上海究本科技有限公司 | Murine Akkermansia muciniphila 139 strain and application thereof |
| CN111690044B (en) * | 2020-05-06 | 2022-03-01 | 中南大学湘雅二医院 | Application of Amuc1100 protein |
| WO2022094847A1 (en) * | 2020-11-05 | 2022-05-12 | 中国科学院深圳先进技术研究院 | Cell lysis solution of engineering bacterium and use thereof in tumor therapy |
| BE1029502B1 (en) * | 2021-08-19 | 2023-01-17 | The Akkermansia Company | Composition comprising pasteurized Akkermansia muciniphila for the treatment or prevention of anxiety related to irritable bowel syndrome |
| CN113925854B (en) * | 2021-08-25 | 2023-06-23 | 武汉益鼎天养生物科技有限公司 | Application of chlorogenic acid in preparation of Anaerosticpes growth promoter |
| CN115252749A (en) * | 2022-03-26 | 2022-11-01 | 吉林大学 | Application of aconite root preparation for regulating middle warmer as antidepressant targeting medicine |
| CN115300571A (en) * | 2022-07-26 | 2022-11-08 | 深圳市第二人民医院(深圳市转化医学研究院) | Antidepressant pharmaceutical composition, preparation method and application thereof |
| CN117065002B (en) * | 2023-02-02 | 2024-03-22 | 浙江大学 | Application of Acremonium membrane protein Amuc_1100 in preparation of product for preventing and/or treating age-related cognitive decline |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101740893B1 (en) * | 2014-05-20 | 2017-06-13 | 주식회사 엠디헬스케어 | COMPOSITION COMPRISING EXTRACELLULAR VESICLES DERIVED FROM Akkermansia muciniphila AS AN ACTIVE INGREDIENT FOR TREATING OR PREVENTING METABOLIC DISEASE |
| EA201700507A1 (en) * | 2015-05-06 | 2018-05-31 | Университе Католик Де Лувен | COMPOSITION, CELLS, METHODS OF OBTAINING POLYPEPTIDE, APPLICATION OF POLYPEPTIDE AND CELLS, METHOD OF TREATMENT |
| CN105030841A (en) * | 2015-08-24 | 2015-11-11 | 上海交通大学医学院附属瑞金医院 | Application of Akkermansia muciniphila BAA-835 strain |
| DK3443071T3 (en) * | 2016-04-11 | 2022-01-31 | Univ Wageningen | HIRELY UNKNOWN BACTERIAL SPECIES |
| AU2017370681A1 (en) * | 2016-12-06 | 2019-06-27 | Pendulum Therapeutics, Inc. | Methods and compositions relating to isolated and purified microbes |
| AU2017382197B2 (en) * | 2016-12-20 | 2022-12-01 | The Regents Of The University Of California | Compositions and methods for inhibiting seizures |
| CN110227085A (en) * | 2019-07-16 | 2019-09-13 | 江苏省中医院 | Application of the Akkermansia Muciniphila in preparation antidepressant or health care product |
-
2019
- 2019-07-16 CN CN201910639110.5A patent/CN110227085A/en active Pending
- 2019-11-18 CN CN201911126003.9A patent/CN110693917B/en active Active
-
2020
- 2020-03-17 WO PCT/CN2020/079604 patent/WO2021008149A1/en active Application Filing
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021008149A1 (en) * | 2019-07-16 | 2021-01-21 | 江苏省中医院 | Application of akkermansia muciniphila in preparation of antidepressant drug or health care product |
| CN111938158A (en) * | 2020-08-18 | 2020-11-17 | 王意 | Composition for preventing reduction of abundance of Akkermansia muciniphila bacteria in intestinal tract |
| CN113322202A (en) * | 2021-05-31 | 2021-08-31 | 君维安(武汉)生命科技有限公司 | Ackermanella, culture method and application thereof |
| CN113322202B (en) * | 2021-05-31 | 2022-03-01 | 君维安(武汉)生命科技有限公司 | Ackermanella, culture method and application thereof |
| WO2023123613A1 (en) * | 2021-12-30 | 2023-07-06 | 浙江大学 | Bipolar affective disorder biomarker and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021008149A1 (en) | 2021-01-21 |
| CN110693917A (en) | 2020-01-17 |
| CN110693917B (en) | 2020-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110227085A (en) | Application of the Akkermansia Muciniphila in preparation antidepressant or health care product | |
| US10925905B2 (en) | Modulation of fat storage in a subject by altering population levels of Christensenellaceae in the GI tract | |
| Choi et al. | Spatial heterogeneity and stability of bacterial community in the gastrointestinal tracts of broiler chickens | |
| Miquel et al. | Faecalibacterium prausnitzii and human intestinal health | |
| Arora et al. | Diabetes-associated microbiota in fa/fa rats is modified by Roux-en-Y gastric bypass | |
| Kimoto‐Nira | New lactic acid bacteria for skin health via oral intake of heat‐killed or live cells | |
| US11666607B2 (en) | Nanovesicles derived from Faecalibacterium prausnitzii and uses thereof | |
| Diaz et al. | Identification of Lactobacillus strains with probiotic features from the bottlenose dolphin (Tursiops truncatus) | |
| CN111415705A (en) | Method and medium for making related intestinal flora detection report | |
| CN114540229A (en) | Lactobacillus paracasei strain for enhancing treatment effect of immune checkpoint inhibitor and application thereof | |
| US20110112048A1 (en) | Use of beta-glucan on upper respiratory tract infection symptoms and psychological well-being | |
| Hao et al. | The biological regulatory activities of Flammulina velutipes polysaccharide in mice intestinal microbiota, immune repertoire and heart transcriptome | |
| Toukam et al. | In vivo antimalarial activity of a probiotic bacterium Lactobacillus sakei isolated from traditionally fermented milk in BALB/c mice infected with Plasmodium berghei ANKA | |
| Castro et al. | Preliminary studies on the prevention of the ovalbumin-induced allergic response by Enterococcus faecalis CECT7121 in mice | |
| CN103919815A (en) | Use of probiotic bacteria for the preparation of a composition for the elimination of uremic toxins | |
| CN111617061A (en) | Application of spermidine in preparation of preparation for improving abundance of lachnospirillum bacteria | |
| El-Shanshory et al. | Al-hijamah (the triple S treatment of prophetic medicine) exerts cardioprotective, tissue-protective and immune potentiating effects in thalassemic children: a pilot clinical trial | |
| Weng et al. | Effects of Pretreatment with Bifidobacterium bifidum using 16S ribosomal RNA gene sequencing in a mouse model of acute colitis induced by dextran sulfate sodium | |
| CN107496438A (en) | Application of the Phellinus polysaccharide in medicine and health food is prepared | |
| CN108159090A (en) | Purposes of the lucidum spore powder dietary fiber extract in treatment and/or prevention intestinal bacilli illness relevant disease preparation is prepared | |
| McEvoy et al. | Nutrition resilience for healthy ageing | |
| US20220186292A1 (en) | Nano-vesicle derived from catenibacterium bacteria and use thereof | |
| US10441612B2 (en) | Intestinal microbe therapy, composition therefor and method for preparing the same | |
| CN103301520A (en) | Method and device for treating blood cholesterol disorders | |
| KR102230479B1 (en) | Nanovesicles derived from Turicibacter bacteria and Use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190913 |
|
| WD01 | Invention patent application deemed withdrawn after publication |